Perspectives of stem cell use in reconstructive maxillofacial surgery

Cover Page

Abstract


The discovery of stem cells is one of the greatest achievements of molecular and cell biology, and associated research has confirmed the possibility of self-renewal and differentiation into specialized tissue stem cells. The use of cellular technologies is an important trend in modern medicine. The aim of this article is to briefly review current findings on the use of stem cells in cardiology, endocrinology, neurology, traumatology, and maxillofacial surgery. All data were retrieved from experimental and clinical studies using various cell technologies. The material is part of ongoing maxillofacial surgery research to investigate the possible use of stem cells in reconstructive maxillofacial surgery for jaw bone pathologies in children. Present tissue engineering methods provide some opportunities for solving difficult clinical problems in oral and maxillofacial surgery. Despite some international achievements of effective application of IC in various diseases, clinical use in reconstructive surgery requires further investigation.


Perhaps, the greatest contribution to discovery of stem cells (SC) was made by Alexander Alexandrovich Maksimov (1874-1928), the Russian scientist, histologist, and the propounder of the unitary theory of hematopoiesis. Maksimov noted that over the lifetime of a human body, poorly differentiated cells, which are approaching transformation into embryonic mesenchymal cell lineage, are retained around the small vessels. Later, he called these cells as the “stem cells”, a term that refers to their location in the “trunk”, which is the base of the hematopoietic tree [1, 2].

A. Y. Friedenstein and I. L. Chertkov discovered two types of multipotent stem cells in the bone marrow (BM MSC): hematopoietic stem cells (HSC), the precursors of all blood cell types, and the stromal (mesenchymal) stem cells (SSC) that rarely divide. Their findings are summarized in the monograph “Cell fundamentals of hematopoiesis (hematopoietic progenitor cells”) [3-5].

An article by James Thomson (USA, 1998) published in the journal Science surmised the possibility of isolation of embryonic stem cells (ESCs) from the human blastocysts. Simultaneously, similar studies were published by John Gerhart (USA). According to the journal Science, isolation of ESC and their in vitro cultivation (propagation in a culture medium in special vials) was the third most important discovery in biology after the decoding of the DNA double helix and the completion of the mapping of the human genome [3].

The concept of stem cells. Stem cell refers to a progenitor cell with the ability to self-renew and differentiate into specialized tissues.

In the literature, stem cells are classified [4, 6-10] on the basis of their ability to differentiate or on the basis of their origin.

According to their ability for differentiation, there are following types of stem cells:

  • totipotent cells, which differentiate into a complete organism. These refer to the embryonic cells and the cells of the extraembryonic structures before implantation (11th day after fertilization);
  • pluripotent cells, which differentiate into various organ or tissue elements. These are embryonic cells from the post-implantation period to the 8th week, inclusive;
  • multipotent cells, which are the precursors of cells of several types;
  • unipotent cells, which retain the ability to differentiate into only one type of cells.

The following types of stem cells are distinguishable on the basis of their origin:

  • embryonic stem cells – these are stem cells isolated during the early stages of embryogenesis (at the stage of blastocyst or the germ of the 5-week-old embryos) or teratocarcinoma (tumor line) in vitro;
  • fetal stem cells are found in the umbilical cord blood and the placenta and are differentiate into different cell types;
  • stem cells found in the adult organism: hematopoietic stem cells in hematopoietic organs and blood, which differentiate into different germs of hematopoiesis. Mesenchymal (stromal) stem cells are located in the bone marrow; they are capable of differentiation into osteoblasts, chondrocytes, tenocytes, adipocytes, myoblasts, and fibroblasts. Stem cells are also present in other tissues (regional SC), such as the skin, blood vessels and nervous tissue, and these retain the ability to differentiate into corresponding cell types.

ESCs are considered the most primitive stem cells which are formed by the 5th day after fertilization, as the inner cell mass. These have a high potential to differentiate into and reproduce other types of cells. The unresolved legal and ethical issues associated with their use and the lack of ability to harvest ESCs suitable for clinical use has constrained the use of ESCs. Furthermore, ESCs express most of its genome “in random manner”.

ESCs enabled for the first time the verification of the source of chondrocytes. In the course of embryogenesis in situ the predominant cell mass of cartilage tissue is formed from the mesenchymal stem cells (MSCs). Under influence of a certain set of signals, cultured totipotent cells of teratocarcinoma of the ESC line of mice were shown to differentiate into chondrocytes and adipocytes [11]. Under the influence of certain other signals, totipotent human MSCs were shown to readily differentiate into adipocytes [12].

The scientists actively conduct the studies in the field of obtaining pluripotent somatic cells of animals and humans. Two basic ways of achieving this are described. The first involves the use of cloning methods such as cell fusion, transfer of somatic cell nuclei in the oocyte of the second meiotic division (somatic cell nuclear transfer, SCNT) [13]; the second method involves reprogramming to obtain induced pluripotent stem cells (induced pluripotent stem cells, iPS cells) which are similar to ESCs [13, 14]. In 2006, Japanese scientists managed to obtain the first SCs which do not differ in their properties from ESCs of mammals.

Studies in the field of tissue engineering and tissue regeneration are performed using the embryonic stem cells, induced pluripotent and somatic stem cells. However, autologous MSCs isolated from bone marrow, adipose tissue, skin, umbilical cord and placenta have found immense clinical application, the seminal impact of which is reflected in the tens of millions of therapeutic transplantations performed for various diseases. Embryonic stem and induced pluripotent cells are not used in clinical practice due to a number of limitations which include their genomic instability and tumorigenicity.

The International Society for Cellular Therapy (ISCT) has established minimum criteria for characterization of MSCs [15]. MSCs is a group of heterogeneous cells, adhesive to the plastic substrate, which are isolated from bone marrow, adipose tissue, placenta, umbilical cord blood or any other tissue. The name MSC merely connotes the mesenchymal origin of these cells and does not necessarily imply a restricted potential for differentiation. Four stromal cell populations are heterogeneous, and only a small number of these have properties of stem cells or those similar to them” [16, 17].

MSCs can be isolated from various tissues, such as muscle and embryonic connective tissues [18]. However, the ability to isolate MSCs from adipose tissue in virtually any amounts from individuals with different body types is considered the most promising, for example during lipoaspiration [19]. About 2-6 × 108 cells can be obtained from 1 cm3 of adipose tissue. More than 300 cm3, that is about 150 × 109 karyocytes can be isolated from one donor. Such a volume of MSCs is adequate for therapeutic use without the need for prior cultivation. Further, the concentration of the desired phenotype MSCs can be increased during cultivation by a factor of hundreds. To isolate a set of osteogenic precursor cells, beta-glycerophosphate (donor of inorganic phosphate), ascorbic acid and dexamethasone are added to the standard culture. Similarly, insulin, beta-transforming growth factor and ascorbic acid are used for chondrocyte growth [19].

Due to their multipotency, SCs are able to differentiate into different lineages, osteogenic, chondrogenic and adipogenic, that can be used for the development of new cellular biomedical technologies. The ability to produce a wide variety of cell types makes them the most important restorative reserve in the body, which is used for defect replacement.

Clinical application. Use of SC is one of the most promising developments in modern medicine. A considerable amount of scientific studies have demonstrated the high efficacy of the use of SCs in a number of diseases, including those that affect the maxillo-facial area. At the same time, the direct application of SCs raises many questions related to statutory compliance, the risk of malignancy in the process of their cultivation and during the post-transplant period, as well as those that relate to the regulation of cell differentiation [20].

The Ministry of Health of the Russian Federation considered the next version of the draft of the federal law “On circulation of biomedical cell technologies” (Federal Law “On biomedical cell products” dated 06/23/2016 number 180 FZk) [21, 22], which regulates the relations that arise in connection with the development, preclinical and clinical studies, examination, state registration, production, storage, disposal, use, the application monitoring, import in the Russian Federation, the export of biomedical cell products from Russia.

Each MSC pattern used for therapeutic purpose is evaluated from the perspective of the presence of favorable biological properties and the safety of their use in a particular clinical situation. The purity of the resulting culture is assessed by MSC immunophenotyping. Then the biological properties and safety of the MSCs obtained in vitro is evaluated against a number of criteria. The proliferative potential of the cells obtained is assessed (culture techniques, cytochemical methods for determining the aging of cells, molecular-genetic methods), the ability of multipotent mesenchymal stromal cells (MMSC) to differentiate in vitro and the expression of genes involved in differentiation is evaluated. The interaction of MMSC with other cells is evaluated as is their genetic stability and tumorigenic potential (cardiological examination with the detection of genomic and chromosomal aberrations, molecular and genetic study is conducted for the detection of mutations in genes and oncogenes and the tumor suppressors). Finally, the microbiological safety is assessed (bacteriological and virological studies) [23, 24].

The ability of MSCs to differentiate is their essential feature. The differentiation potential is determined in the course of cell culture under special conditions, with detection of specific changes in the direction of differentiation [25].

For the treatment of neurodegenerative diseases and rehabilitation of patients with acute and chronic disorders of cerebral circulation the ability of MSCs to undergo neuron-like differentiation is of much interest [26].

The prospects for use of MSCs with ability for cardiomyogenetic differentiation for regenerative therapy for cardiovascular diseases are being evaluated [27]. In recent experimental and clinical studies, the effect of MSCs on the course of cardiovascular diseases was shown to be mediated via their paracrine effect, i.e., by production of cytokines that promote sustainability of cardiomyocytes under hypoxic and apoptotic conditions [28]. Use of the bone marrow SCs for reconstitution of human heart valve tissue is envisaged. This technique holds immense promise for the future to grow from the SCs of a full heart for transplantation to patients (UK, 2007). Full-structure capillary blood vessels are grown from human embryonic SCs (Japan, 2004). AngioStem technology for cord blood SC transplantation for restoration of blood vessels, and clinical studies of the treatment of peripheral arterial diseases with autologous bone marrow SCs were conducted (Indiana Center, 2007) [29]. The most effective methods of transplantation of autologous myoblasts and bone marrow SCs are in the heart tissue. Medical centers in Europe, Asia, the US and Russia have experience of transplantation.

Neonatal MSCs were found to have an ability to differentiate in hepatocyte-like cells, which can also be obtained from adult sources. The possibility of the use of MSCs for histotypic restoration of liver tissue is studied [30]. According to the studies, MSCs increase the trophism of hepatocytes and reduce the level of apoptosis by their paracrine effect [31]. The ability to differentiate into the cells of the pancreatic islets enables the use of MSCs in the treatment of diabetes mellitus. Due to their immunomodulatory properties, therapeutic MSCs transplantation in autoimmune type I diabetes is possible [32, 33].

Use in orthopedics, traumatology, maxillo-facial surgery and dentistry. The osteogenic differentiation of MSCs involves the ability of these cells to develop into osteoblasts, which is promising for the use of MMSCs in providing reparative regeneration of the bone tissue, including for the treatment of imperfect osteogenesis. To induce the osteogenic differentiation of MMSC, dexamethasone, ascorbic acid and β-glycerophosphate is added to the culture medium. MMSC differentiation into osteoblasts is confirmed by the expression of alkaline phosphatase and the presence of extracellular calcium salt precipitates [15, 34].

A study by P. Janickietal et al. (2011) revealed that MSCs of different donors have different osteogenic potential. The osteogenic potential of MSCs obtained from various tissue sources is also different. The evaluation of osteogenic potency was performed by determination of alkaline phosphatase in the cell lysate of the MSC culture on Day 7, 14 and 21 of osteogenic induction. The chondrogenic differentiation of MSC opens the prospects of clinical application of the cells to restore cartilaginous tissue, especially of articular cartilages. The chondrogenic differentiation of MSCs is inducible in vitro, by the addition of basic fibroblast growth factor (bFGF), TGFβ3 and bone morphogenetic protein-2 (BMP-2) to the culture medium. Chondrogenesis can be confirmed in vitro on staining with gossypimine or alcian blue, to determine glucosaminoglycan content, which is the major component of the amorphous substance of the cartilage extracellular matrix [35, 36].

The individual use of MSCs in traumatology and orthopedics to supplement their deficiency or to stimulate bone formation has not found wide application till date, as it appeared to be inefficient. However, the biomimetic principle can be used to further develop their use [37]. According to it, to restore the bone defect the hybrid implant is used, which consists of a carrier (hydroxylapatite, tricalcium phosphate, collagen, polymers, and others), MSCs and a growth factor, predominantly BMP and/or TGF [38-40]. The experiments on ectopic bone formation show that this mechanism can operate in direct and indirect mode. In the first case, it contains exogenous MSCs, and in the second case, the SCs migrate from the surrounding tissues and accumulate on the carrier [41].

According to some authors, SCs can be used for the treatment of severe forms of arthrosis, until full recovery. Stem cells enhance blood supply to the diseased joints and improve the body metabolism. Joint pain in arthrosis is significantly reduced when SCs are administered intravenously. On local administration of SCs in the joint the pain syndrome can be completely arrested. The efficacy of SCs in treating arthrosis and concomitant diseases approaches an average of 85%, with the results clinically evident immediately. SCs have found application in the treatment of spinal osteochondrosis, via activation of regenerative processes in the affected vertebrae [42, 43].

MSCs are used more often in adult patients with musculoskeletal disorders. In case of violation of the integrity of the cartilage cover after injury or as a result osteochondropathy, an early degenerative-dystrophic damage of the joint occurs. Local administration of cells by injection into the joint cavity with 1-2 mL of patient’s blood plasma or the intra-articular fluid taken from a patient’s healthy large joint. The minimally invasive method supplements the articular cartilage defects, creates conditions for optimization of reparative processes in the most severe and frequent damages to the joints. Also, this method is used in combination with surgical treatment, which involves MSCs transplant. During the treatment the cartilage grows in size, receives adequate nutrition due to diffusion of substances from the synovial fluid, and allows complete replacement of the hyaline cartilage defect (the materials from the stem cell bank of Pokrovskaya hospital, C). Similar method was developed and is used in patients with pathology of large joints at the N.N. Priorov Central research institute of traumatology and orthopaedics in Moscow. Osteotomy of shin bone and calf-bone was performed with their subsequent distraction. During osteotomy, the patient’s bone marrow was obtained. In the laboratory, MSCs were isolated and cultured from the bone marrow. Three weeks after the osteotomy, 5 mL of physiological solution with 5 million MSCs was administered to the target site for regeneration during distraction. The treatment course comprised of five injections at intervals of 5-7 days.

This approach involves the use of a cell culture enriched with MSCs, or the MSC culture cultured in vitro. The cell expansion in vitro is necessary to obtain an effective dose of MSCs. The clinical efficiency of use of cells is demonstrable in spondylodesis with bone auto-grafting and surface application of a suspension of autologous MSCs with β-tricalcium phosphate. A method referred to as “injectable bone” (BM MSCs in the gel of plasma enriched with platelets) is being developed for simultaneous augmentation of the alveolar process and placing the dental implant [44].

In maxillo-facial surgery, BM MSCs are used to repair the bone tissue more often than the other cell types [34]. The regenerative potential of BM MSCs was demonstrated both in experimental studies [45, 46] and in clinical studies [47]. An important feature of MSCs is their immunosuppressive effect on T- and B-cells and natural killer cells which may be useful in the treatment of pathologies of the mesenchymal tissue and also to suppress the possible inflammatory response to components of the tissue engineering product. Y. Yamada et al. (2008) [48] used autologous BM MSCs in their clinical and experimental studies and showed high efficiency of bone defect recovery. In an experiment on dogs [49], this group of researchers created 10-mm deep bone defects on the surface of the alveolar part of the mandible, where the bone bone-replacing materials were implanted. The following series of experiments were performed: use of plasma enriched with platelets (PRP); BM MSCs together with PRP; MSC of a temporary tooth together with PRP; MSC of a dental papilla together with PRP; a control series without bone bone-replacing material. The degree of bone regeneration and the implant resorption was examined histologically at weeks 2, 4 and 8. The control defect and the defect with a PRP-implant showed a low rate of bone formation, while the defects filled with BM MSCs together with PRP, MSC of a temporary tooth/PRP, MSC of dental papilla/PRP showed a good degree of bone regeneration [50].

Donor zones. MSCs can be obtained from adipose tissue, as this tissue is more easily-accessible biological material compared with the bone marrow, which is the main source of MSCs. The material obtained from adipose tissue is better suited for use in traumatology and orthopedics, as it can be differentiated more effectively into bone cells. In addition, adipose tissue MSCs can stimulate the vascular growth through secretion of the vascular endothelial growth factor (VEGF), which confers greater efficacy (the material from the stem cell bank of Pokrovskaya hospital).

The germ and the pulp of the third molar teeth and temporary human teeth can be used as sources of SCs. This biological material is completely accessible, and the cell populations in are similar to adipose tissue MSCs and are capable of proliferation both in vitro and in vivo and are multipotent. According to the study results, cells from the human third molar germs have properties similar to those of MSCs, express high levels of mRNA genes of transcription factors, which is characteristic of pluripotent SCs, and are able to differentiate into adipogenic, chondrogenic, osteogenic and neuronal lines.

One of the interesting fields in tissue engineering, including maxillo-facial surgery, is the use of scaffolds. Scaffolds are three-dimensional porous or fibrous matrices that perform the function of a mechanical frame for cells. Such materials include natural polymers (collagen, cellulose, fibronectin, chitosan, alginate and agarose, fibroin), synthetic polymers (polylactide, polyglycolide, polycaprolactone, polyvinyl alcohol) and bioceramics (hydroxyapatite, tricalcium phosphate and bioactive glass). Particular attention has been paid recently to innovative technologies of rapid prototyping, that is processes of formation of three-dimensional object based on a digital model, the most usable of biopolymers are laser stereolithography, selective laser sintering, fused deposition modeling and 3D-printing. In the process of producing bioengineered structures based on scaffolds (SC planting on the matrices prior to their transplantation to the site of defect) bioactive substances that induce osteogenic differentiation and attract new cells of the carrier, as well as stimulate angiogenesis are used. These substances are mainly represented by various growth factors [51-53].

Review of the scientific literature has shown that during the last decade, the attention of clinicians is increasingly drawn to such “ideal” grafting materials as autologous MSCs. Undoubtedly, this material cannot but catch the interest of surgeons dealing with reparative and restorative surgery for pediatric patients. The multipotency of MSCs and their ability to differentiate into chondrogenic and especially osteogenic directions can provide over the long term a virtually unlimited amount of grafting material, which will solve one of the most difficult tasks in reconstructive surgery of the skeleton in children, which is the problem of choice of the autologous bone-replacing material.

For more complete judgment on the regenerative possibilities for tissue engineering in restoration of bone defects, more preclinical and clinical studies are necessary consistently under the control of informative clinical, laboratory and morphological methods of studies allowing to evaluate in dynamics the manifestation and direction of regenerative processes.

Despite the certain international experience of effective application of SCs in various diseases, mainly for therapeutic and cosmetic purposes, their clinical use in surgery requires further research.

Mikhail G. Semyonov

The Turner Scientific and Research Institute for Children’s Orthopedics, Saint Petersburg; North-Western State Medical University n. a. I.I. Mechnikov, Saint Petersburg

Author for correspondence.
Email: sem_mikhail@mail.ru

Russian Federation MD, PhD, рrofessor, head of the department of maxillofacial surgery and surgical dentistry n.a. A.A. Limberg of the North-Western State Medical University n.a. I.I.Mechnikov. Leading research associate of the of the department of maxillofacial surgery. The Turner Scientific and Research Institute for Children’s Orthopedics

Yulia V. Stepanova

The Turner Scientific and Research Institute for Children’s Orthopedics, Saint Petersburg

Email: turner8ord@gmail.com

Russian Federation MD, PhD, chief of the department of maxillofacial surgery

Darya О. Troshchieva

North-Western State Medical University n. a. I.I. Mechnikov, Saint Petersburg

Email: troschieva_dariya@mail.ru

Russian Federation MD, PhD student of the department of maxillofacial surgery and surgical dentistry named after A.A. Limberg

  1. Клишов А.А. Научная деятельность профессора А.А. Максимова в Военно-медицинской академии // Арх. анат. — 1988. — Т. 95. — Вып. 12. — С. 86–89. [Klishov AA. Nauchnaya deyatelnost professora A.A. Maksimova v voenno-meditsinskoy akademii. Arh. anat. 1988;95(12):86-89. (In Russ.)]
  2. Мяделец О.Д., Кичигина Т.Н. А.А. Максимов и его революционное учение о мезенхимальных стволовых клетках // Вестник ВГМУ. — 2007. — Т. 6. — № 3. — С. 139–147. [Myadelets OD, Kichigina TN. A.A. Maksimov i ego revolyutsionnoe uchenie o mezenhimalnyih stvolovyih kletkah. Vestnik VGMU. 2007;6(3):139-147. (In Russ.)]
  3. Вермель А.Е. Стволовые клетки: общая характеристика и перспективы применения в клинической практике // Клиническая медицина. — 2004. — № 1. — С. 5–11 [Vermel AE. Stvolovyie kletki: obschaya harakteristika i perspektivyi primeneniya v klinicheskoy praktike. Klinicheskaya meditsina. 2004;1:5-11. (In Russ.)]
  4. Зуева Е.Е., Куртова А.В., Комарова Л.С. Стволовые клетки. Некоторые биологические особенности и терапевтические возможности // Гематология. — 2005. — Т. 6. — С. 705–724. [Zueva EE. Kurtova AV, Komarova LS. Stvolovyie kletki. Nekotoryie biologicheskie osobennosti i terapevticheskie vozmozhnosti. Gematologiya. 2005;6:705-724. (In Russ.)]
  5. Фриденштейн А.Я., Лалыкина К.С. Индукция костной ткани и остеогенные клетки-предшественники. — М.: Медицина, 1973. — 220 с. [Fridenshteyn AYa, Lalyikina KS. Induktsiya kostnoy tkani i osteogennyie kletki-predshestvenniki. Moscow: Meditsina; 1973. 220 p. (In Russ.)]
  6. Белоусов Ю.Б. Некоторые актуальные проблемы клинических исследований стволовых клеток // Этическая экспертиза биомедицинских исследований. — 2005. — Т. 7. — № 1. — С. 131–138. [BelousovYuB. Nekotoryie aktualnyie problemyi klinicheskih issledovaniy stvolovyih kletok. Eticheskaya ekspertiza biomeditsinskih issledovaniy. 2005;7(1):131-138. (In Russ.)]
  7. Кузнецов С.Л., Мушкамбаров Н.Н., Горячкина В.Л. Атлас по гистологии, цитологии и эмбриологии. — М.: МИА, 2002. [Kuznetsov SL, Mushkambarov NN, Goryachkina VL. Atlas po gistologii, tsitologii i embriologii. Moscow: MIA; 2002. (In Russ.)]
  8. Мезен Н.И., Квачева З.Б., Сычик Л.М. Стволовые клетки: Учебно-методическое пособие. — Минск: БГМУ, 2014. [Mezen NI, Kvacheva ZB, Syichik LM. Stvolovyie kletki. Uchebno-metodicheskoe posobie. Minsk: BGMU; 2014. (In Russ.)]
  9. Хэм А., Кормак Д. Гистология / Пер. с англ. — М.: Мир, 1983. — Т. 3. — 292 с. [Hem A, Kormak D. Gistologiya. Translation from English. Moscow: Mir; 1983;3:292. (In Russ.)]
  10. Шахов В.П. Введение в методы культуры клеток, биоинженерии органов и тканей. — Томск, 2004. — 385 с. [Shahov VP. Vvedenie v metodyi kulturyi kletok, bioinzhenerii organov I tkaney. Tomsk; 2004. 385 p. (In Russ.)]
  11. Kramer J, Hegert C, Guan K, et al. Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4. Mech. Dev. 2000;92:193-205. doi: 10.1016/S0925-4773(99)00339-1.
  12. Репин В.С., Ржанинова А.А., Шаменков Д.А. Эмбриональные стволовые клетки: фундаментальная биология и медицина. — М.: Реметэкс, 2002. — С. 79–83 [Repin VS, Rzhaninova AA, Shamenkov DA. Embrionalnyie stvolovyie kletki: fundamentalnaya biologiya i Meditsina. Moscow: Remeteks; 2002; p. 79-83. (In Russ.)]
  13. Byrne JA, et al. Producing primate embryonic stem cells by somatic cell nuclear transfer. Nature. 2007;450:497-502. doi: 10.1038/nature06357.
  14. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;5:861-872. doi: 10.1016/j.cell.2007.11.019.
  15. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. PNAS. 2002;99:8932. doi: 10.1073/pnas.132252399.
  16. Нимер С.Н. Стволовые клетки (обзор литературы) // Проблемы здоровья и экологии. — 2009. — № 1. — С. 46–51. [Nimer SN. Stem cells (references review). Health and Environment Issues. 2009;(1):46-51. (In Russ.)]
  17. Pate DW, Southerland SS, Gande DA, et al. Isolation and differentiation of mesenchymal stem cells from rabbit muscle. Surg Forum.1993;43:587.
  18. Lucas PA, Calcutt AF, Ossi P, et al. Mesenchymal stem cells from granulation tissue. J Cell Biochem. 1993;17E:122.
  19. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering. 2001;4(2):211-228. doi: 10.1089/107632701300062859.
  20. Смолянинов А.Б. Современные условия становления рынка клеточных технологий России и его развитие // Вестник Росздравнадзора. — 2009. — № 6. — С. 38–44. [Smolyaninov AB. Sovremennyie usloviya stanovleniya ryinka kletochnyih tehnologiy Rossii i ego razvitie. Vestnik Roszdravnadzora. 2009;(6):38-44. (In Russ.)]
  21. О биомедицинских клеточных технологиях. Проект ФЗ РФ от 18 января 2013 г. [O biomeditsinskihkletochnyihtehnologiyah. Proekt FZ RF from 18.01.2013. (In Russ.)]
  22. Федеральный закон от 23 июня 2016 г. № 180-ФЗ «О биомедицинских клеточных продуктах» [Federalnyiy zakon ot 23 iyunya 2016. No 180-FZ “O biomeditsinskih kletochnyih produktah”. (In Russ.)]
  23. Шахпазян Н.К., Астрелина Т.А., Яковлева М.В. Мезенхимальные стволовые клетки из различных тканей человека: биологические свойства, оценка качества и безопасности для клинического применения // Клеточная трансплантология и тканевая инженерия. — 2012. — Т. 7. — № 1. — С. 23–33. [Shahpazyan NK, Astrelina TA, Yakovleva MV. Mesenchymalstem cells from various human tissues: biological properties, assessment of quality and safetyfor clinical use. Kletochnaya transplantologiya I tkanevaya inzheneriya. 2012;7(1):23-33. (In Russ.)]
  24. Lee CH, Shah B, Moioli EK, Mao JJ. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. J Clin Invest. 2010;120(9):3340-3349. doi: org/10.1172/jci43230.
  25. Квачева З.Б. Стволовые клетки. Перспективы их применения в медицине // Медицинский журнал. — 2005. — № 4. — С. 4–6. [Kvacheva ZB. Stem cells. Prospects of their use in medicine. Meditsinskiy zhurnal. 2005;4(14):4-6. (In Russ)]
  26. Cai S, Shea GK, Tsui AY, et al. Derivation of clinically applicable schwann cells from bone marrow stromal cells for neural repair and regeneration. CNS Neurol Disord Drug Targets. 2011;10(4):500-8. doi: 10.2174/187152711795563930.
  27. Соколова И.Б., Павличенко Н.Н. Механизмы воздействия экзогенных мезенхимальных стволовых клеток на ишемизированную ткань при сердечно-сосудистых заболеваниях // Цитология. — 2010. — Т. 52. — № 11. — С. 911–917. [Sokolova IB, Pavlichenko NN. Possible ways of MSCs influence on the ishemic tissue in the case of cardiovascular diseases. Tsitologiya. 2010;52(11):911-7. (In Russ)]
  28. Chen TS, Lai RC, Lee MM, et al. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010;38(1):215-24. doi: 10,1093 / NAR / gkp857.
  29. Li Q, Turdi S, Thomas DP, et al. Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction. Toxicol Lett. 2010;195(2-3):119-26. doi: org/10.1016/j.toxlet.2010.03.009.
  30. Puglisi MA, Saulnier N, Piscaglia AC, et al. Adipose tissuederived mesenchymal stem cells and hepatic differentiation: old concepts and future perspectives. Eur Rev Med Pharmacol Sci. 2011;15(4):355-64.
  31. Kanazawa H, Fujimoto Y, Teratani T, et al. Bone marrowderived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One. 2011;6(4):e19195. doi: 10.1371/journal.pone.0019195.
  32. Aurich I, Mueller LP, Aurich H, et al. Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut. 2007;56:405-15. doi: 10.1136/gut.2005.090050.
  33. Vija L, Farge D, Gautier JF, et al. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab. 2009;35(2):85-93. doi: 10.1016/j.diabet.2008.10.003.
  34. Janicki P, Boeuf S, Steck E, et al. Prediction of in vivo bone forming potency of bone marrow-derived human mesenchymal stem cells. Eur Cell Mater. 2011;21:488-507.
  35. Giovannini S, Diaz-Romero J, Aigner T, et al. Micromass co-culture of human articular chondrocytes and human bone marrow mesenchymal stem cells to investigate stable neocartilage tissue formation in vitro. Eur Cell Mater. 2010;20:245-59.
  36. Miyaki S, Nakasa T, Otsuki S, et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum. 2009;60(9):2723-30. doi: 10.1002/art.24745.
  37. Hench L. Lead presentation: biomimetic processing: a critical review. Sixth World biomaterial congress, 15-20 May 2000. Hawaii, USA, 2000. P. 404.
  38. Орлов А.А., Сабурина И.Н. Репин В.С., и др. Экспериментальное моделирование 3-D заданного остеогенеза костной ткани на базе аутологичных культур мультипотентных мезенхимальных стромальных клеток крысы остеопластических материалов для устранения дефектов кости // Вестник новых медицинских технологий. — 2011 — Т. 18. — № 1. — С. 70–11. [Orlov AA, Saburina IN, Repin VS, et al. Experimental modeling 3-d target osseous tissue osteogenesis on the basis of autologous cultures of multipotential mesenchymal stromal rat cells and osteoplastic materials for eliminating bone defects. Journal of New Medical Technologies. 2011;18(1):7-11. (In Russ.)]
  39. Попков А.В. Биосовместимые имплантаты в травматологии и ортопедии (обзор литературы) // Гений ортопедии. — 2014. — № 3. — С. 94–99 [Popkov AV. Biocompatible implants in traumatology and orthopaedics (A review of literature). Orthopaedic Genius. 2014;(3):94-99. (In Russ.)]
  40. Han B, Reyes O, Tang BW, et al. Recombinant osteogenin with collagen binding domain composted with porous resorbable ceramic stimulates repair of bone and carti-lages in dogs. Sixth World biomaterial congress, 15-20 May 2000. Hawaii, USA, 2000. P. 490.
  41. Vehof JM, Mahmood J, Takita H, et al. Ectopic bone formation in BMP-loated calcium Phosphate-coated titanium mesh. Sixth World biomaterial congress, 15-20 May 2000. Hawaii, USA, 2000. P. 640. doi: org/10.1097/00006534-200108000-00024.
  42. Иванов Д.В., Хадарцев А.А., Хадарцев В.А., и др. Клиническое использование стволовых клеток // Вестник новых медицинских технологий. — 2009 — Т. 16. — № 4. — С. 31–33. [Ivanov DV, Hadartsev AA, Hadartsev VA, et al. Сlinical Usage of Stem Cells. Journal of New Medical Technologies. 2009;16(4):31-33. (In Russ.)]
  43. Омельянченко Н.П., Илизаров Г.А., Стецулла В.И. Регенерация костной ткани. Травматология и ортопедия: Руководство для врачей / Под ред. Ю.Г. Шапошникова. — М.: Медицина, 1997. — С. 393–482. [Omelyanchenko NP, Ilizarov GA, Stetsulla VI. Regeneratsiya kostnoy tkani. Travmatologiya I ortopediya: Rukovodstvo dlya vrachey. Ed. Yu.G. Shaposhnikov. Moscow: Meditsina; 1997. P. 393-482. (In Russ.)]
  44. Gan Y, Dai K, Zhang P, et al. The clinical use of enriched bone marrow stem cells combined with porous β-tricalcium phosphate in posterior spinal fusion. Biomaterials. 2008;29(29):3973-3982. doi: 10.1016/j.biomaterials.2008.06.026.
  45. Люндуп А.В., Медведев Ю.А., Баласанова К.В., и др. Методы тканевой инженерии костной ткани в челюстно-лицевой хирургии // Вестник РАМН. — 2013. — № 5. — С. 10–15. [Lyundup AV, Medvedev YuA, Balasanova KV, et al. Methods of Tissue Engineering of Bone Tissue in Maxillofacial Surgery. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2013;(5):10-15. (In Russ.)]. doi: 10.15690/vramn.v68i5.658.
  46. Люндуп А.В., Онищенко Н.А., Шагидулин М.Ю., Крашенинников М.Е. Стволовые прогениторные клетки печени и костного мозга как регуляторы восстановительной регенерации поврежденной печени // Вестн. трансплантол. и искусств. органов. — 2010. — T. 12. — № 2. – С. 100–107. [Lyundup AV, Onischenko NA, Shagidulin MYu, Krasheninnikov ME. Liver and bone marrow stem/progenitor cells as regulators of reparative regeneration of damaged liver. Vestnik Transplantologii i Iskusstvennykh Organov. 2010;12(2):100-107. (In Russ.)]. doi: 10.15825/1995-1191-2010-2-100-107.
  47. Macchiarini P, Jungebluth P, Go T, et al. Clinical transplantation of a tissue-engineered airway. Lancet. 2008;372(9655):2023-2030. doi: 10.1016/S0140-6736(08)61598-6.
  48. Yamada Y, Nakamura S, Ito K, et al. Injectable tissue-engineered bone using autogenous bone marrow-derived stromal cells for maxillary sinus augmentation: clinical application report from a 2-6-year follow-up. Tissue Eng. Part A. 2008;14(10):1699-707. doi: org/10.1089/ten.tea.2007.0189.
  49. Yamada Y, Ito K, Nakamura S, et al. Promising cell-based therapy for bone regeneration using stem cells from deciduous teeth, dental pulp, and bone marrow. Cell Transplant. 2011;20(7):1003-1013. doi: 10.3727/096368910X539128.
  50. Kaigler D, Pagni G, Park ChH, et al. Stem Cell Therapy for Craniofacial Bone Regeneration: A Randomized, Controlled Feasibility Trial. Cell Transplant. 2013;22(5):767-777. doi: org/10.3727/096368912x652968.
  51. Кузнецова Д.С., Тимашев П.С., Баграташвили В.Н., Загайнова Е.В. Костные имплантаты на основе скаффолдов и клеточных систем в тканевой инженерии (обзор) // Современные технологии в медицине. — 2014. — Т. 6. — № 4. — С. 201–212. [Kuznetsova DS, Timashev PS, Bagratashvili VN, Zagaynova ЕV. Scaffold- and cell system-based bone grafts in tissue engineering (Review). Sovremennye tehnologii v medicine. 2014;6(4):201-212. (In Russ.)]
  52. Садовой М.А., Ларионов П.М., Самохин А.Г., Рожнова О.М. Клеточные матрицы (скаффолды) для целей регенерации кости: современное состояние проблемы // Хирургия позвоночника. — 2014. — № 2. — С. 79–86. [Sadovoy MA, Larionov PM, Samohin AG, Rozhnova OM. Cellular matrices (scaffolds) for bone regeneration: state of the art. Spine Surgery. 2014:2:79-86. (In Russ.)]. doi: 10.14531/ss2014.2.79-86.
  53. Стволовые клетки и регенеративная медицина / Под ред. В.А. Ткачука. — М.: Макс‐пресс, 2012. — 88 c. [Stvolovye kletki I regenerativnaya medicina. Ed. V.A. Tkachuka. Moscow: Maks‐press; 2012. 88 p. (In Russ.)]

Views

Abstract - 907

PDF (Russian) - 656

PDF (English) - 164

Cited-By


PlumX


Copyright (c) 2016 Semyonov M.G., Stepanova Y.V., Troshchieva D.О.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies